395 related articles for article (PubMed ID: 23824675)
1. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir.
Cottrell ML; Hadzic T; Kashuba AD
Clin Pharmacokinet; 2013 Nov; 52(11):981-94. PubMed ID: 23824675
[TBL] [Abstract][Full Text] [Related]
2. Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors.
Podany AT; Scarsi KK; Fletcher CV
Clin Pharmacokinet; 2017 Jan; 56(1):25-40. PubMed ID: 27317415
[TBL] [Abstract][Full Text] [Related]
3. Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection.
Rathbun RC; Lockhart SM; Miller MM; Liedtke MD
Ann Pharmacother; 2014 Mar; 48(3):395-403. PubMed ID: 24259658
[TBL] [Abstract][Full Text] [Related]
4. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.
Shah BM; Schafer JJ; Desimone JA
Pharmacotherapy; 2014 May; 34(5):506-20. PubMed ID: 24347095
[TBL] [Abstract][Full Text] [Related]
5. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
[TBL] [Abstract][Full Text] [Related]
6. Adverse drug reactions to integrase strand transfer inhibitors.
Lepik KJ; Yip B; Ulloa AC; Wang L; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
AIDS; 2018 Apr; 32(7):903-912. PubMed ID: 29424784
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology of HIV integrase inhibitors.
Adams JL; Greener BN; Kashuba AD
Curr Opin HIV AIDS; 2012 Sep; 7(5):390-400. PubMed ID: 22789987
[TBL] [Abstract][Full Text] [Related]
8. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.
Ndashimye E; Avino M; Olabode AS; Poon AFY; Gibson RM; Li Y; Meadows A; Tan C; Reyes PS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Arts EJ
J Antimicrob Chemother; 2020 Dec; 75(12):3525-3533. PubMed ID: 32853364
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques.
Massud I; Martin A; Dinh C; Mitchell J; Jenkins L; Heneine W; Pau CP; García-Lerma JG
J Antimicrob Chemother; 2015 May; 70(5):1473-81. PubMed ID: 25630643
[TBL] [Abstract][Full Text] [Related]
10. Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics.
DeAnda F; Hightower KE; Nolte RT; Hattori K; Yoshinaga T; Kawasuji T; Underwood MR
PLoS One; 2013; 8(10):e77448. PubMed ID: 24146996
[TBL] [Abstract][Full Text] [Related]
11. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.
d'Arminio Monforte A; Cozzi-Lepri A; Di Biagio A; Marchetti G; Lo Caputo S; Rusconi S; Gianotti N; Mazzotta V; Mazzarello G; Costantini A; Castagna A; Antinori A;
J Antimicrob Chemother; 2019 May; 74(5):1363-1367. PubMed ID: 30698801
[TBL] [Abstract][Full Text] [Related]
12. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.
Bollen PDJ; Moore CL; Mujuru HA; Makumbi S; Kekitiinwa AR; Kaudha E; Parker A; Musoro G; Nanduudu A; Lugemwa A; Amuge P; Hakim JG; Rojo P; Giaquinto C; Colbers A; Gibb DM; Ford D; Turkova A; Burger DM;
Lancet HIV; 2020 Aug; 7(8):e533-e544. PubMed ID: 32763217
[TBL] [Abstract][Full Text] [Related]
13. [Mechanisms of action, pharmacology and interactions of dolutegravir].
Ribera E; Podzamczer D
Enferm Infecc Microbiol Clin; 2015 Mar; 33 Suppl 1():2-8. PubMed ID: 25858605
[TBL] [Abstract][Full Text] [Related]
14. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.
Tsiang M; Jones GS; Goldsmith J; Mulato A; Hansen D; Kan E; Tsai L; Bam RA; Stepan G; Stray KM; Niedziela-Majka A; Yant SR; Yu H; Kukolj G; Cihlar T; Lazerwith SE; White KL; Jin H
Antimicrob Agents Chemother; 2016 Dec; 60(12):7086-7097. PubMed ID: 27645238
[TBL] [Abstract][Full Text] [Related]
15. Dolutegravir for the treatment of adult patients with HIV-1 infection.
Wu G; Abraham T; Saad N
Expert Rev Anti Infect Ther; 2014 May; 12(5):535-44. PubMed ID: 24694091
[TBL] [Abstract][Full Text] [Related]
16. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
[TBL] [Abstract][Full Text] [Related]
17. The Promise of Dolutegravir: A Novel Second Generation Integrase Strand Transfer Inhibitor.
Singh H; Kaur M; Kakkar AK; Kumar H
Curr Clin Pharmacol; 2016; 11(2):88-94. PubMed ID: 27157040
[TBL] [Abstract][Full Text] [Related]
18. Tolerability of HIV integrase inhibitors.
Lee FJ; Carr A
Curr Opin HIV AIDS; 2012 Sep; 7(5):422-8. PubMed ID: 22886031
[TBL] [Abstract][Full Text] [Related]
19. Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review.
Podany AT; Scarsi KK; Pham MM; Fletcher CV
Clin Pharmacokinet; 2020 Sep; 59(9):1085-1107. PubMed ID: 32462541
[TBL] [Abstract][Full Text] [Related]
20. Paediatric Integrase Inhibitor Use in a Real-Life Setting: A Single-Centre Cohort Experience 2009-2018.
Abo YN; Refsum E; Mackie N; Lyall H; Tudor-Williams G; Foster C
Clin Drug Investig; 2019 Jun; 39(6):585-590. PubMed ID: 30976998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]